Aptar Pharma’s Nanopharm will develop the formulation and inhalation strategy for Aceso Therapeutics’ preclinical ACT-101 antisense drug, which aims to stabilize CFTR mRNA rather than edit DNA.
A Nature Biotechnology analysis of 42 rentosertib-treated IPF trial participants found younger predicted biological-age profiles across six proteomic clocks, but researchers caution that the finding does not prove human aging was reversed.
Cipla’s Invagen has licensed U.S. rights to Qilu’s investigational pembrolizumab biosimilar QL2107, setting up a future challenge to Merck’s blockbuster Keytruda franchise.
An NYU Langone study of more than 3.5 million children found rapidly increasing off-label GLP-1 prescribing below age 12, concentrated among children with severe obesity and related disease.
Menarini has licensed European rights to Gan & Lee’s twice-monthly GLP-1 bofanglutide after a 640-patient Phase 3 study produced up to 18.54% mean weight loss at 52 weeks.
Clover’s 420-patient Phase 2 trial found strong antibody responses to RSV, hMPV and PIV3 with no apparent immune interference, supporting further development of its multi-virus vaccines for older adults.
FDA feedback supports major elements of Matricelf’s proposed first-in-human NewRal study in chronic complete thoracic spinal cord injury while requesting additional IND information.
Novartis and Ionis say pelacarsen substantially reduced lipoprotein(a) but failed to reduce major cardiovascular events in the 8,323-patient Phase 3 Lp(a)HORIZON trial.
Kali Therapeutics has received FDA IND clearance for KT501, a CD19xBCMAxCD3 trispecific T-cell engager designed to produce deep B-cell and plasma-cell depletion in autoimmune disease.
Mabwell’s 80-patient Phase 1b/2a COPD trial showed an 81% numerical reduction in moderate-to-severe exacerbations at the highest 9MW1911 dose, supporting Phase 2b and planned Phase 3 development.